$218.85 meals Payment -- Takeda Pharmaceuticals to Dr. Michelle Scott

Takeda Pharmaceuticals provides $218.85 in meals to a Rare Disease specialist.

This page provides a detailed analysis of a $218.85 meals payment from Takeda Pharmaceuticals to Dr. Michelle Scott. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$218.85
Payment Typemeals
Payment NatureFood and Beverage
Pharmaceutical CompanyTakeda Pharmaceuticals
PhysicianDr. Michelle Scott
NPI Number1034714199
Physician SpecialtyRare Disease
LocationCity, CO
Date of Payment2024-12-06
Conflict AssessmentLow -- Routine

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Takeda Pharmaceuticals made a $218.85 meals payment to Michelle Scott, a Rare Disease specialist in City, CO. The payment of $218.85 from Takeda Pharmaceuticals to Dr. Michelle Scott was for meals. This payment occurred on December 6, 2024, and was categorized as Food and Beverage. Dr. Scott's specialty is Rare Disease, and the payment was made in Colorado.

Patient Guidance: What This Payment Means for You

This information relates to a meal provided by a pharmaceutical company; it does not directly impact your medical care. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

For a Rare Disease specialist, a meal payment of this amount is generally considered low and typical for educational or informational interactions.

Regulatory Context: Sunshine Act Requirements

This payment falls under the Sunshine Act's reporting requirements for transfers of value from pharmaceutical manufacturers to physicians.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding meals Payments

Food and beverage payments cover meals provided to physicians during pharmaceutical sales representative visits, medical conferences, and educational events. While individual meal payments tend to be small (often under $100), research published in JAMA Internal Medicine has shown that even modest meals can be associated with changes in prescribing behavior. Meal payments are the most common type of pharmaceutical payment to physicians.

Frequently Asked Questions About This Payment

What was this $218.85 payment for?

This was a meals payment of $218.85 from Takeda Pharmaceuticals to Michelle Scott, categorized as "Food and Beverage". The payment was reported under the Sunshine Act (CMS Open Payments).

Does Michelle Scott accept pharmaceutical money?

Yes, Michelle Scott received this $218.85 payment from Takeda Pharmaceuticals. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Michelle Scott's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this meals payment?

A meals payment of $218.85 is generally routine and common in the industry. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Rare Disease?

To compare this payment against Rare Disease averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Rare Disease physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Michelle Scott's relationship with Takeda Pharmaceuticals?

The payment amount is relatively small, suggesting a routine meal expense. This $218.85 meals payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Rare Disease?

The payment type is 'meals', a common form of interaction between pharma and physicians.

What should patients do after learning about this payment?

This information relates to a meal provided by a pharmaceutical company; it does not directly impact your medical care.

What else should I know about this meals payment?

The date of payment is in the future, which is unusual for a completed transaction.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.